Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

Brian Skorney, an analyst from Robert W. Baird, maintained the Buy rating on RegenXBio (RGNX – Research Report). The associated price ...

Gain insight on Rigel Pharmaceuticals, AbbVie and more in the latest Market Talks covering the Health Care sector.

Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.

Parent Project Muscular Dystrophy, a nonprofit that seeks to accelerate research ... potential treatments and that these ...

Detailed price information for Satellos Bioscience Inc (MSCL-T) from The Globe and Mail including charting and trades.

Netflix flexes documentary muscle with eight projects in the running for an Oscar, but National Geo, others have strong ...

“We need help from other people,” pleaded Pavlina. “We saw videos from the children who were already there, it [the treatment ...

EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...

Edgewise Therapeutics, Inc. ( (EWTX) ) has released its Q3 earnings. Here is a breakdown of the information Edgewise Therapeutics, Inc.

Despite a net loss, WAVE Life Sciences Ltd (WVE) showcases promising clinical progress and a strengthened financial position ...